JP5026633B2 - 細胞増殖の阻害のための置換ビスインドリルマレイミド類 - Google Patents

細胞増殖の阻害のための置換ビスインドリルマレイミド類 Download PDF

Info

Publication number
JP5026633B2
JP5026633B2 JP2000536713A JP2000536713A JP5026633B2 JP 5026633 B2 JP5026633 B2 JP 5026633B2 JP 2000536713 A JP2000536713 A JP 2000536713A JP 2000536713 A JP2000536713 A JP 2000536713A JP 5026633 B2 JP5026633 B2 JP 5026633B2
Authority
JP
Japan
Prior art keywords
indol
methyl
nitro
mmol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000536713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506864A5 (US06894165-20050517-C00155.png
JP2002506864A (ja
Inventor
ディングラ,ウルヴァシ・ホーダ
フリン,ドナ・メアリー
ケ,ジューン
ウェーバー,ジュセッペ・フェデリコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2002506864A publication Critical patent/JP2002506864A/ja
Publication of JP2002506864A5 publication Critical patent/JP2002506864A5/ja
Application granted granted Critical
Publication of JP5026633B2 publication Critical patent/JP5026633B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2000536713A 1998-03-17 1999-03-10 細胞増殖の阻害のための置換ビスインドリルマレイミド類 Expired - Lifetime JP5026633B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7833198P 1998-03-17 1998-03-17
US60/078,331 1998-03-17
PCT/EP1999/001534 WO1999047518A1 (en) 1998-03-17 1999-03-10 Substituted bisindolymaleimides for the inhibition of cell proliferation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010126632A Division JP2010222366A (ja) 1998-03-17 2010-06-02 細胞増殖の阻害のための置換ビスインドリルマレイミド類

Publications (3)

Publication Number Publication Date
JP2002506864A JP2002506864A (ja) 2002-03-05
JP2002506864A5 JP2002506864A5 (US06894165-20050517-C00155.png) 2006-04-27
JP5026633B2 true JP5026633B2 (ja) 2012-09-12

Family

ID=22143350

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000536713A Expired - Lifetime JP5026633B2 (ja) 1998-03-17 1999-03-10 細胞増殖の阻害のための置換ビスインドリルマレイミド類
JP2010126632A Pending JP2010222366A (ja) 1998-03-17 2010-06-02 細胞増殖の阻害のための置換ビスインドリルマレイミド類

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010126632A Pending JP2010222366A (ja) 1998-03-17 2010-06-02 細胞増殖の阻害のための置換ビスインドリルマレイミド類

Country Status (34)

Country Link
US (1) US6048887A (US06894165-20050517-C00155.png)
EP (1) EP1064279B1 (US06894165-20050517-C00155.png)
JP (2) JP5026633B2 (US06894165-20050517-C00155.png)
KR (1) KR100659411B1 (US06894165-20050517-C00155.png)
CN (1) CN1127500C (US06894165-20050517-C00155.png)
AR (1) AR018162A1 (US06894165-20050517-C00155.png)
AT (1) ATE243693T1 (US06894165-20050517-C00155.png)
AU (1) AU755673B2 (US06894165-20050517-C00155.png)
BR (1) BR9908882A (US06894165-20050517-C00155.png)
CA (1) CA2322689C (US06894165-20050517-C00155.png)
CO (1) CO5070675A1 (US06894165-20050517-C00155.png)
CZ (1) CZ299068B6 (US06894165-20050517-C00155.png)
DE (1) DE69909068T2 (US06894165-20050517-C00155.png)
DK (1) DK1064279T3 (US06894165-20050517-C00155.png)
ES (1) ES2203111T3 (US06894165-20050517-C00155.png)
HK (1) HK1036452A1 (US06894165-20050517-C00155.png)
HR (1) HRP20000585B1 (US06894165-20050517-C00155.png)
HU (1) HU228831B1 (US06894165-20050517-C00155.png)
ID (1) ID26353A (US06894165-20050517-C00155.png)
IL (1) IL138247A (US06894165-20050517-C00155.png)
MA (1) MA26613A1 (US06894165-20050517-C00155.png)
MY (1) MY121046A (US06894165-20050517-C00155.png)
NO (1) NO320306B1 (US06894165-20050517-C00155.png)
NZ (1) NZ506476A (US06894165-20050517-C00155.png)
PE (1) PE20000340A1 (US06894165-20050517-C00155.png)
PL (1) PL195323B1 (US06894165-20050517-C00155.png)
PT (1) PT1064279E (US06894165-20050517-C00155.png)
RS (1) RS49965B (US06894165-20050517-C00155.png)
RU (1) RU2208612C2 (US06894165-20050517-C00155.png)
SA (1) SA99191295B1 (US06894165-20050517-C00155.png)
TR (1) TR200002580T2 (US06894165-20050517-C00155.png)
TW (1) TW539676B (US06894165-20050517-C00155.png)
WO (1) WO1999047518A1 (US06894165-20050517-C00155.png)
ZA (1) ZA992072B (US06894165-20050517-C00155.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222366A (ja) * 1998-03-17 2010-10-07 F Hoffmann La Roche Ag 細胞増殖の阻害のための置換ビスインドリルマレイミド類

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
MXPA02003667A (es) * 1999-10-12 2002-08-30 Hoffmann La Roche Pirroles sustituidos como agentes antiproliferativos para tratamiento del cancer.
US6559164B1 (en) 1999-10-12 2003-05-06 Hoffmann-La Roche Inc. Substituted pyrroles suitable for continuous infusion
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
WO2008117935A1 (en) * 2007-03-28 2008-10-02 Industry-Academic Cooperation Foundation, Yonsei University Nk cell activating molecules, nk cells and pharmaceutical compositons comprising the same
CN102924437B (zh) * 2012-11-19 2014-07-02 东华大学 3-哌嗪基-4-吲哚马来酰亚胺化合物及其制备和应用
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91598A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) * 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
ATE243693T1 (de) * 1998-03-17 2003-07-15 Hoffmann La Roche Substituierte bisindolylmaleimide zur inhibierung der zellproliferation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222366A (ja) * 1998-03-17 2010-10-07 F Hoffmann La Roche Ag 細胞増殖の阻害のための置換ビスインドリルマレイミド類

Also Published As

Publication number Publication date
PL195323B1 (pl) 2007-09-28
SA99191295B1 (ar) 2006-04-26
ZA992072B (en) 1999-09-22
CN1293671A (zh) 2001-05-02
NO20004579L (no) 2000-09-14
MY121046A (en) 2005-12-30
RS49965B (sr) 2008-09-29
PE20000340A1 (es) 2000-05-13
CA2322689A1 (en) 1999-09-23
IL138247A (en) 2005-08-31
PL342964A1 (en) 2001-07-16
AR018162A1 (es) 2001-10-31
CN1127500C (zh) 2003-11-12
CO5070675A1 (es) 2001-08-28
WO1999047518A1 (en) 1999-09-23
KR20010041995A (ko) 2001-05-25
AU3409999A (en) 1999-10-11
HRP20000585B1 (en) 2009-02-28
ATE243693T1 (de) 2003-07-15
HRP20000585A2 (en) 2001-08-31
DK1064279T3 (da) 2003-10-06
CZ20003384A3 (cs) 2000-12-13
NO320306B1 (no) 2005-11-21
JP2002506864A (ja) 2002-03-05
YU55200A (sh) 2002-11-15
HK1036452A1 (en) 2002-01-04
HUP0101258A3 (en) 2002-08-28
DE69909068D1 (de) 2003-07-31
ES2203111T3 (es) 2004-04-01
IL138247A0 (en) 2001-10-31
TW539676B (en) 2003-07-01
HUP0101258A2 (hu) 2001-10-28
DE69909068T2 (de) 2004-05-06
AU755673B2 (en) 2002-12-19
JP2010222366A (ja) 2010-10-07
EP1064279A1 (en) 2001-01-03
CA2322689C (en) 2008-11-25
KR100659411B1 (ko) 2006-12-18
CZ299068B6 (cs) 2008-04-16
MA26613A1 (fr) 2004-12-20
ID26353A (id) 2000-12-14
US6048887A (en) 2000-04-11
NZ506476A (en) 2003-12-19
TR200002580T2 (tr) 2000-11-21
EP1064279B1 (en) 2003-06-25
HU228831B1 (en) 2013-05-28
PT1064279E (pt) 2003-10-31
NO20004579D0 (no) 2000-09-14
RU2208612C2 (ru) 2003-07-20
BR9908882A (pt) 2000-11-21

Similar Documents

Publication Publication Date Title
JP2010222366A (ja) 細胞増殖の阻害のための置換ビスインドリルマレイミド類
CA2996318C (en) Heteroaryl compounds as irak inhibitors and uses thereof
TW202115065A (zh) Kras突變蛋白抑制劑
WO2011106632A1 (en) Substituted hydroxamic acids and uses thereof
PT1389617E (pt) Composto heterocíclico e agente antitumoral contendo o mesmo como igrediente activo
US6252086B1 (en) 4-alkenyl-and 4-alkynyloxindoles
CA3092625A1 (en) Heteroaryl compounds as type ii irak inhibitors and uses thereof
AU718844B2 (en) New pharmaceutically active compounds
JP7299382B2 (ja) Tnf活性のモジュレーターとしての縮合五環式イミダゾール誘導体
TW202210488A (zh) 吡嗪類衍生物及其在抑制shp2中的應用
WO1995027699A1 (fr) Derive d'aminostilbazole et medicament
SI9300542A (en) Benzofuran derivatives for medical use
KR20000029627A (ko) 세포증식을억제하는치환된비스인돌릴말레이미드
MXPA00008923A (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
KR101634758B1 (ko) 에스트로겐 수용체 리간드로서의 2-하이드록시-7-메틸 옥타하이드로페난트렌 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 약학 조성물
WO1997046515A1 (fr) Benzenes substitues ne presentant pas d'effets inhibiteurs
BR112018003343B1 (pt) Compostos heteroarila como inibidores de irak e composição farmacêutica compreendendo os mesmos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120621

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150629

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term